to-BBB receives Michael J. Fox Foundation funding for Parkinson’s disease research

24-Apr-2012 - Netherlands
to-BBB has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct preclinical research targeting neuroinflammation in Parkinson’s disease (PD) with its second product in development, 2B3-201. This is to-BBB’s first grant from MJFF.
“We strongly believe that we can create better treatment options for devastating brain diseases faster by safely enhancing the delivery of existing, proven effective, drugs across the blood-brain barrier. Neuroinflammation plays an important role in the pathogenesis and progression of various neurological disorders, including PD. It is a major acknowledgement from MJFF to support us to target such a novel approach in PD. This grant will provide to-BBB with the opportunity to pursue Proof of Concept of 2B3-201 in PD, and we look forward to collaborating with the Foundation,” said Pieter Gaillard, Chief Scientific Officer of to-BBB.
to-BBB aims to demonstrate the improved effect of its brain-targeted long-circulating liposomal formulation of methylprednisolone (2B3-201) in established preclinical models of PD. Methylprednisolone is known to be a very effective drug in reducing acute neuroinflammation, however, its widespread use is limited by the well-known acute and chronic side effects of glucocorticoids. In preliminary preclinical studies, 2B3-201 has already shown to significantly better reduce neuroinflammation in preclinical models as compared to similar doses of free methylprednisolone. This was accomplished by a sustained higher brain penetration at a low effective dose, with demonstrable less side effects, thereby significantly improving the therapeutic index of the treatment.

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?